Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 5Terminated 3Active not recruiting 2Withdrawn 1Suspended 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1

Conditions

Sarcoma, Synovial 1Sarcoma 1Neurofibrosarcoma 1Liposarcoma 1Leiomyosarcoma 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 436Carboplatin 321Nivolumab 287Cyclophosphamide 280Specimen Handling 257Cisplatin 251Paclitaxel 248Magnetic Resonance Spectroscopy 248Radiotherapy 217Gemcitabine 180Dexamethasone 180Biopsy 177durvalumab 166atezolizumab 148Rituximab 138Lenalidomide 134Doxorubicin 134Docetaxel 130Bevacizumab 129Ipilimumab 125Radiation 118Capecitabine 117Pemetrexed 112Oxaliplatin 112Etoposide 111Radiosurgery 108Fluorouracil 108venetoclax 106fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × sotigalimab × Clear all
NCT04495257 2025-10-30

A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)

Yale University

Phase 1 Active not recruiting
26 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT03719430 2025-04-29

APX005M and Doxorubicin in Advanced Sarcoma

Columbia University

Phase 2 Active not recruiting
27 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡